Week in Review: Eddingpharm Pays $169 Million for China Rights to Omega-3 Drug

Eddingpharm of China signed a deal worth up to $169 million for China rights to Vascepa®, a prescription omega-3 drug from Amarin of the US;  Georgia State University out-licensed China rights for a potential leukemia-fighting drug to Cisen Pharma, headquartered in Shandong Province; Eisai of Japan announced plans to build a second new plant in the Suzhou Industrial Park to make oral solid dose products; TWi Pharma of Taiwan reacquired US distribution rights to two of its products from Teva, which TWi will now market itself; and MicuRx Pharma, a US-China company, was granted FDA approval to begin a US Phase II trial of its novel oral antibiotic, which MicuRx will pair with a similar China trial already underway. More details.... Stock Symbols: (NSDQ: AMRN) (TO: 4523) (TW: 4180) (NYSE: TEVA) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.